Panel Discussion: How to Characterise Rational Biomarkers/Endpoints?
Time: 3:30 pm
day: Day Two
Details:
- Exploring biomarker selection – clinical presence of inflammation in the diseases
- Utility in assessing disease progression and control of disease
- What is a clinically meaningful benchmark of inflammasome inhibition?
- What are the best tissue biomarkers of inflammasome inhibition?
- What biomarkers and assays should be measured in a phase 1 or phase 2 trial to demonstrate inflammasome inhibition?
- Overcoming the challenge of a lack of biomarkers to enable early intervention in disease
- Validating assays in knockout models and testing assays in biological (plasma/serum) samples
- Thoughts on future directions of this space and how companies can cover as many diseases as possible
